Abstract 990P
Background
Hepatic arterial infusion chemotherapy (HAIC) is known to be more effective than conventional systemic chemotherapy, showing great potential in treating unresectable hepatocellular carcinoma (HCC) patients. However, there is still unclear which group can benefit more from HAIC.
Methods
191 patients with unresectable HCC undergoing HAIC from Zhongshan Hospital between May 2019 and March 2022 were retrospectively recruited. Radiomics scores were calculated based on enhanced-T1-weighted, enhanced-T2-weighted, arterial phase and delayed phase images. Clinical factors related to OS and PFS were identified by Cox regression analysis. Three different CNNs of AlexNet, ResNet, and Inception architectures were constructed on 70% of the data set and tested on the remaining 30%. Radiomics scores and clinical factors were reflected to a model eventually. Mean squared error (MSE) and time-dependent receiver operating characteristic curve were calculated for the models.
Results
The OS model included radiomics score with No. of HAIC cycles, tumor thrombus, PIVKA-II, neutrophil-lymphocyte ratio (NLR), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (γ-GT) and C-reactive protein. And the PFS model included radiomics score with No. of HAIC cycles, tumor thrombus, NLR and γ-GT. The AlexNet-OS model, ResNet-OS model, and Inception-OS model achieved the best MSE of 1.0068, 0.9023 and 0.8506, respectively. The AlexNet-PFS model, ResNet- PFS model, and Inception- PFS model achieved the best MSE of 0.6658, 0.6819 and 1.1012, respectively.
Conclusions
The present models which integrated radiomics information and clinical factors helped predict OS and PFS of unresectable HCC patients undergoing HAIC treatment.
Clinical trial identification
Editorial acknowledgement
We are very grateful to Mrs. Hailin Mi for helping us to construct the deep learning model. Hailin Mi kindly provided statistical advice for this manuscript. (Hailin Mi; Department of Computer Science and Technology, Harbin Engineering University, China)
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China (No. 81972889, Dr Yin).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18